CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and to the Board’s Audit Committee.
“Dr. Gardner’s very broad and deep expertise in medicine, biotechnology, and corporate investing and governance is an ideal skill set for the CohBar Board as we strategically advance our portfolio and pipeline of mitochondrial peptides and disease targets,” said Albion Fitzgerald, Chairman of the Board. “We are very excited about working with her to realize the full potential of CohBar’s unique science in the development of novel therapeutics that treat age-related diseases, extend healthy life span and increase longevity.”
About Dr. Phyllis Gardner
Dr. Gardner brings to the CohBar Board over 35 years of experience in academia, medicine, pharmacology, drug delivery systems, and biotechnology investing and governance, and has received numerous national awards and honors. She is currently a tenured professor at the School of Medicine at Stanford University, where she has served in various positions since 1984, including as Senior Associate Dean for Education and Student Affairs, and is a member of the board of directors of the Harvard Medical School of Fellows and Advisory Council on Education. Dr. Gardner has served as a director of Revance Therapeutics, Inc. (NASDAQ: RVNC) since December 2008, and previously served on the board of directors of Corium International, Inc., a biopharmaceutical company formerly listed on the NASDAQ, from November 2007 to November 2018. From 1999 to 2014, she served as an adjunct partner, then partner at Essex Woodlands Health Ventures, a healthcare growth equity and venture capital firm. From 1994 to 1998, Dr. Gardner took a leave of absence from Stanford to work at ALZA Corporation as a Principal Scientist, Vice President of Research and as Head of ALZA Technology Institute. She previously served as a director of Parnell Pharmaceuticals Holdings Ltd. (OTCMKTS: PARNF), BioMarin Pharmaceutical, Inc., a NASDAQ listed company, Aerogen Limited, and Aronex Pharmaceuticals.
Dr. Gardner received her bachelor’s degree in biology from the University of Illinois and her doctor of medicine from Harvard Medical School, and has completed research fellowships in the departments of Pharmacology at the College of Physicians and Surgeons at Columbia University and University College, London, U.K. She trained in internal medicine at Massachusetts General Hospital, followed by a Chief Residency at Stanford University Medical Center. Dr. Gardner’s research has centered on cardiac arrhythmias, ion channel biophysiology, cell biology, cystic fibrosis pathogenesis, gene therapy and diagnosis, and her clinical work has concentrated on medicine and cardiology, including cardiac arrhythmia, heart failure and cardiac transplantation.
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for its lead candidate program, including anticipated timing and results of IND-enabling activities and clinical trials; statements regarding the therapeutic potential of these and other mitochondria based therapeutics, and the potential for additional discoveries, and our plans and expectations regarding intellectual property protection. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. Such assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor and Media Contact:
Jon Stern, COO
LifeSci Advisors, LLC
Released February 11, 2019